ARA-290
For nerve pain that burns or tingles and will not settle. Built from EPO without the blood effects; small human trials, slow build.
What it is
ARA-290 is for the person with small-fiber nerve pain, the burning feet, pins and needles, or skin that hurts to touch, who has tried the usual things. It also gets used for stubborn inflammation. It works slowly, over weeks, and it is one of the few research peptides with actual human trials behind it.
The people who reach for it have neuropathy: diabetic nerve pain, the small-fiber neuropathy that comes with sarcoidosis, post-chemo tingling, or a nerve injury that healed badly. A second group uses it for chronic inflammatory conditions where BPC-157 helped a bit but not enough. It is not a general recovery peptide for gym aches; BPC-157 and TB-500 cover that better and cheaper.
This is a slow one. Most people notice nothing in week one. Around weeks two to four the burning quiets at night first, then daytime symptoms ease; in the human studies the nerve measures kept improving across the full month of dosing. Good looks like fewer bad nights and being able to wear shoes or socks comfortably again, not zero pain. It will not regrow a severed nerve or fix a mechanical problem like a pinched disc.
Dose is 2 mg once a day subQ for most people, 4 mg if 2 mg has done nothing by week three. The subQ human trials dosed 4 mg a day for 28 days (one sarcoidosis trial also tested 1 and 8 mg), so you are at least using a number that has been in people. Take it any time of day, food does not matter. Reconstitute a 10 mg vial with 3 ml, the most the vial takes, so 2 mg is 60 units, and expect it to look a little cloudy; that is normal for this one. A 10 mg vial is five days at 2 mg, so an eight-week run is about eleven vials, which makes this one of the more expensive peptides here per cycle. The common mistake is stopping at two weeks because nothing happened yet.
The evidence is better than most: animal work on nerve and tissue protection, and several small randomized human trials (sarcoidosis small-fiber neuropathy, diabetic neuropathy) with improvements in pain scores and nerve fiber density. It is still unapproved and the trials were small and short, so the honest read is: a real signal in people for nerve pain, unknown durability, and no data for anything else it gets sold for.
If your pain is a joint, a tendon or a muscle, skip this and use BPC-157 or the BPC-157 + TB-500 pair. If it is gut inflammation, KPV is cheaper and more targeted. ARA-290 earns its cost only when nerves are the problem.
What people use it for
Nerve pain
Some evidenceSmall randomized trials in people with sarcoidosis small-fiber neuropathy and diabetic neuropathy reported less pain and, in some, regrowth of small nerve fibers in the skin over about a month of daily dosing. These were dozens of patients, not thousands. For you that means a reasonable chance of partial relief, built slowly.
Inflammation and tissue protection
Some evidenceIt activates the innate repair receptor that EPO uses to protect tissue after injury, without EPO's effect on red blood cells. Animal studies show reduced inflammatory signaling and tissue damage in several models. Human use for general inflammation is extrapolated from the nerve trials.
Blood sugar and cholesterol
Early daysIn the diabetic neuropathy study, HbA1c and cholesterol markers also moved in the right direction. That is one small trial and nobody uses it as a metabolic peptide, but it is worth knowing if you are diabetic and on medication.
How it works
- Used for nerve pain, inflammation, and tissue repair
- Avoids the red-blood-cell effects of EPO, its parent
- Early human studies, including in nerve conditions
- Promising for nerve-related issues, not yet approved
How people use it
Safety, in brief
Things people sometimes notice
- A little redness where you inject
- Mild tiredness in the first week
- Slight lightheadedness right after a dose, which passes
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis